

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Application Number	10/550,196
Filing Date	January 12, 2007
First Named Inventor	Madeleine M. Joullie
Art Unit	1654
Examiner Name	CORDERO GARCIA, MARCELA M.
Attorney Docket Number	1694.0610001/JMC/THN

[illegible]

Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76
		Country Code <sup>3</sup> -Number <sup>4</sup> , Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
	FP2	ES 2 102 322 A1	07-16-1997	Pharma Mar, S.A.		
	FP3	WO 98/17302 A1	04-30-1998	The Board of Trustees of the University of Illinois		
	FP4	WO 98/17302 A1 (Corrected Version)	04-30-1998	The Board of Trustees of the University of Illinois		
	FP5	WO 98/17275 A1	04-30-1998	The Board of Trustees of the University of Illinois		
	FP6	WO 02/02596 A2	01-10-2002	Pharma Mar, S.A.		

1125118 1.DOC

Examiner  
Signature

Date  
Considered

\* EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Transmittal instructions: Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/550,196
				Filing Date	January 12, 2007
				First Named Inventor	Madeleine M. Joulie
				Art Unit	1654
				Examiner Name	CORDERO GARCIA, MARCELA M.
Sheet	1	of	4	Attorney Docket Number	1694.0610001/JMC/THN

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL48	Abdel-Magid, A.F., <i>et al.</i> , "Reductive Amination of Aldehydes and Ketones by Using Sodium Triacetoxyborohydride," <i>Tetrahedron Lett.</i> 31:5595-5598, Pergamon Press plc, UK (1990)	
	NPL49	Abdel-Magid, A.F. & Maryanoff, C.A., "Reductive Amination of Aldehydes and Ketones with Weakly Basic Anilines Using Sodium Triacetoxyborohydride," <i>Synlett.</i> 537-539, Germany (1990)	
	NPL50	Ahuja, D., <i>et al.</i> , "Inhibition of Protein Synthesis by Didemnin B: How EF-1 $\alpha$ Mediates Inhibition of Translocation," <i>Biochemistry</i> 39:4339-4346, American Chemical Society, United States (2000)	
	NPL51	Ahuja, D., <i>et al.</i> , "Inhibition of Protein Synthesis by Didemnins: Cell Potency and SAR," <i>J. Med. Chem.</i> 43:4212-4218, American Chemical Society, United States (2000)	
	NPL52	Campbell, M.J., <i>et al.</i> , "Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)-all-trans retinamide," <i>Brit. J. of Cancer</i> 77:739-744, Cancer Research Campaign, UK (1998)	
	NPL53	Crews, C.M., <i>et al.</i> , "Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis," <i>Proc. Natl. Acad. Sci. USA</i> 93:4316-4319, Natl. Acad. Sci., United States (1996)	
	NPL54	Ding, X., <i>et al.</i> , "Structure-Activity Relationships of Side-Chain Modified Didemnins," <i>Bioorg. Med. Chem. Lett.</i> 11:231-234, Elsevier Science Ltd., United States (2001)	
	NPL55	Ewing, W.R., <i>et al.</i> , "SYNTHETIC STUDIES OF DIDE MNINS. I. REVISION OF THE STEREOCHEMISTRY OF THE HYDROXYISOVALERYLPROPIONYL (HIP) UNIT," <i>Tetrahedron</i> 42:5863-5868, Pergamon Journals Ltd., UK (1986)	
	NPL56	Ewing, W.R., <i>et al.</i> , "SYNTHETIC STUDIES OF DIDE MNINS. IV. SYNTHESIS OF THE MACROCYCLE," <i>Tetrahedron Lett.</i> 30:3757-3760, Maxwell Pergamon Macmillan plc, UK (1989)	
	NPL57	Harris, B.D., <i>et al.</i> , "SYNTHETIC STUDIES OF DIDE MNINS. II. APPROACHES TO STATINE DIAS TEREOMERS," <i>Tetrahedron Lett.</i> 28:2837-2840, Pergamon Journals Ltd., UK (1987)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO		<b>Complete if Known</b>			
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/550,196		
		Filing Date	January 12, 2007		
		First Named Inventor	Madelcine M. Joullic		
		Art Unit	1654		
		Examiner Name	CORDERO GARCIA, MARCELA M.		
Sheet	2	of	4	Attorney Docket Number	1694 0610001/JMC/111N

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	1 <sup>2</sup>
	NPL58	Harris, B.D., et al., "SYNTHETIC STUDIES OF DIDEMNINS. III: SYNTHESIS OF STATINE AND ISOSTATINE STEREOISOMERS," <i>Tetrahedron</i> 44:3489-3500, Pergamon Press plc, UK (1988)	
	NPL59	Jou, G., et al., "Total Synthesis of Dehydrididemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in Peptide Synthesis in Solution," <i>J. Org. Chem.</i> 62:354-366, American Chemical Society, United States (1997)	
	NPL60	Joullié, M.M., et al., "Total Synthesis of (-)-tamandarin B," <i>Tetrahedron Lett.</i> 41:9373-9376, Elsevier Science Ltd., UK (2000)	
	NPL61	Joullié, M.M., et al., "Chemical Defense in Ascidians of the <i>Didemnidae</i> Family," <i>Bioconjugate Chem.</i> 14:30-37, American Chemical Society, United States (2003)	
	NPL62	Li, W.-R. & Joullié, M.M., "The Didemnins: Biological Properties, Chemistry and Total Synthesis," <i>Studies in Natural Products Chemistry</i> , 10:241-302, Elsevier Science Publishers B.V., The Netherlands (1992)	
	NPL63	Mayr, S.C., et al., "Synthesis of New Didemnin B Analogs for Investigations of Structure/Biological Activity Relationships," <i>J. Org. Chem.</i> , 59:5192-5205, American Chemical Society, United States (1994)	
	NPL64	Mayr, S.C., et al., "Synthetic Routes to a Constrained Ring Analog of Didemnin B," <i>J. Org. Chem.</i> 61:1655-1664, American Chemical Society, United States (1996)	
	NPL65	Mayr, S.C., et al., "Synthetic Studies of a Constrained Ring Didemnin Analog," <i>Tetrahedron: Asymmetry</i> 5:519-522, Elsevier Science Ltd., UK (1994)	
	NPL66	Mayr, S.C., et al., "The Cyclic Dipeptide Backbone of the Didemnins," <i>Acta Cryst. C</i> 51:1609-1614, International Union of Crystallography, UK (1995)	
	NPL67	Pfizenmayer, A.J., et al., "SYNTHESIS AND BIOLOGICAL ACTIVITIES OF [N-MeLeu <sup>3</sup> ] DIDEMNIN B," <i>Biog. Med. Chem. Lett.</i> 6:2713-2716, Elsevier Science Ltd., UK (1996)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO		<b>Complete if Known</b>			
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/550,196		
		Filing Date	January 12, 2007		
		First Named Inventor	Madeline M. Joullic		
		Art Unit	1654		
		Examiner Name	CORDERO GARCIA, MARCELA M.		
Sheet	3	of	4	Attorney Docket Number	1694.0610001/JMC/THN

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL68	Portonovo, P., et al., "First Total Synthesis of a Fluorescent Didemnin," <i>Tetrahedron</i> 56:3687-3690, Elsevier Science Ltd., UK (2000)	
	NPL69	Ramanjulu, J.M., et al., "A Facile Synthesis of Benzyl 2-Amino-3-Azido-4-O-p-Methoxybenzyl-6-O-Benzyl-2,3-Dideoxy- $\alpha$ -D-Glucopyranoside: A Key Intermediate in the Formation of a Didemnin B Analog," <i>J. Carbohydrate Chemistry</i> 15:371-381, Marcel Dekker, Inc., United States (1996)	
	NPL70	Ramanjulu, J.M., et al., "Analogues of the $\beta$ -Turn of the Cyclodecapeptide Didemnin B," <i>Tetrahedron Letters</i> 37:311-314, Elsevier Science Ltd., UK (1996)	
	NPL71	Ramanjulu, J.M., et al., "Syntheses of Acyclic Analogs of Didemnin B," <i>Synthetic Communications</i> 27:3259-3272, Marcel Dekker, Inc., United States (1997)	
	NPL72	Ramanjulu, J.M., et al., "Synthesis of a Reduced Ring Analog of Didemnin B," <i>J. Org. Chem.</i> 62:4961-4969, American Chemical Society, United States (1997)	
	NPL73	Ramanjulu, J.M., et al., "Synthetic Studies of a Didemnin B Analog Based on a 2,3-Diamino Sugar Scaffolding," <i>J. Chin. Chem. Soc.</i> 48:1-4, The Chemical Society, Taiwan (2001)	
	NPL74	Schumacher, K.K., et al., "Synthetic studies toward astins A, B and C: Efficient syntheses of <i>cis</i> -3,4-dihydroxyprolines and (-)-(3S,4R)-dichloroproline esters," <i>Tetrahedron: Asymmetry</i> 9:47-53, Elsevier Science Ltd., UK (1998)	
	NPL75	Tarver Jr., J.E., et al., "Total Syntheses of Conformationally Constrained Didemnin B Analogues. Replacements of <i>N</i> , <i>O</i> -Dimethyltyrosine with L-1,2,3,4-Tetrahydroisoquinoline and L-1,2,3,4-Tetrahydro-7-methoxyisoquinoline," <i>J. Org. Chem.</i> 66:7575-7587, American Chemical Society, United States (2001)	
	NPL76	Vera, M.D., et al., "[Lys <sup>+</sup> ] Didemnins as Potential Affinity Ligands," <i>Bioorg. Med. Chem. Lett.</i> 11:13-16, Elsevier Science Ltd., UK (2001)	
	NPL77	Vera, M.D. & Joullic, M.M., "Natural Products as Probes of Cell Biology: 20 Years of Didemnin Research," <i>Medicinal Research Reviews</i> 22:102-145, John Wiley & Sons, Inc., United States (2002)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/550,196
				Filing Date	January 12, 2007
				First Named Inventor	Madeline M. Joullic
				Art Unit	1654
				Examiner Name	CORDERO GARCIA, MARCELA M.
Sheet	4	of	4	Attorney Docket Number	1694.0610001/JMC/THN
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	NPL78	Vera, M.D., <i>et al.</i> , "Synthesis and Biological Evaluation of Didemnin Photoaffinity Analogues," <i>Biorg. Med. Chem. Lett.</i> 11:1871-1874, Elsevier Science Ltd., UK (2001)			
	NPL79	Vervoort, H. & Femel, W., "Tamandarin A and B: New Cytotoxic Dipeptides from a Brazilian Ascidian of the Family Didemnidae," <i>J. Org. Chem.</i> 65:782-792, American Chemical Society, United States (2000)			
	NPL80	Wipf, P., "Synthetic Studies of Biologically Active Marine Cyclopeptides," <i>Chem. Rev.</i> 95:2115-2134, American Chemical Society, United States (1995)			
	NPL81	Xiao, D., <i>et al.</i> , "Total Synthesis of a Conformationally Constrained Didemnin B," <i>J. Org. Chem.</i> 66:2734-2742, American Chemical Society, United States (2001)			
	NPL82	STNEasy/Cplus English language Abstract of Spanish Patent Publication No. ES 2 102 322 A1 (1997), document FP1, Accession No. 1998:169709			

1125067 1.DOC

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.